Kinnear Pharmaceuticals
Pre-clinicalMenu Home Overview Science Pipeline Leadership News Harnessing the Power of the Innate Immune System: Introducing Ceragenins, a Versatile Immunomodulatory drug platform for Eradicating Pseudomonas Aeruginosa and a Range of Bacterial and Fungal Infections in Cystic Fibrosis and other diseases.In 2023 FDA granted our request to designate CSA-131 as a QIDP for the prevention /
About
Menu Home Overview Science Pipeline Leadership News Harnessing the Power of the Innate Immune System: Introducing Ceragenins, a Versatile Immunomodulatory drug platform for Eradicating Pseudomonas Aeruginosa and a Range of Bacterial and Fungal Infections in Cystic Fibrosis and other diseases.In 2023 FDA granted our request to designate CSA-131 as a QIDP for the prevention /
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile